ONCOLYTICS BIOTECH - 500 Beiträge pro Seite

[E-L-Schu]

Frage wer kennt ONCOLYTICS BIOTECH

[Bombenleger]

Oncolytics Biotech ist ein hochriskantes Investment.
Ihr Produkt ist in Phase1-2.Das Produkt das im Test
Krebszellen komplett zerstörte ohne Nebenwirkungen könnte in
einigen Jahren in die Geschichte der Medizin gehen.Die Aussichten
sind absolut gigantisch.Ich würde aber ein Investment in Synsorb Biotech
überlegen,denn die Firma hat 35 Prozent Anteile und ist größter
Anteilseigner.

[Bombenleger]

Oncolytics Biotech Announces Positive Interim
Safety Results from REOLYSIN(R) Phase I
Malignant Glioma Study
Monday December 23, 8:45 am ET

CALGARY, AB, Dec. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC,
NASDAQ: ONCY) (`Oncolytics`) today announced positive interim safety results from the
Phase I component of its clinical study examining the use of REOLYSIN® in the
treatment of recurrent malignant glioma, the most aggressive form of brain cancer. The
Company reported that REOLYSIN® appeared to be well tolerated when surgically
delivered into the brain during the treatment of the first six patients.

Determination of the safety of
REOLYSIN® is the primary purpose
of the Phase I study. The study is
examining the use of a single,
intratumoural injection of
REOLYSIN® delivered using
imaging-guided surgery, in patients
with malignant glioma that has
recurred despite other treatments,
including surgery and radiation
therapy. After treatment with
REOLYSIN®, the Phase I patients
are monitored and evaluated for
safety for a period of six months.
Five of the six treated patients
remain alive and on study with
duration after treatment ranging
between 10 and 25 weeks. One
patient died of progressive disease after leaving the study, but no severe adverse
effects attributable to the virus were seen in this patient.

An independent data safety monitoring board was established at the start of the trial
and recently completed its first scheduled review, which included the results seen in the
first six patients. The board has recommended continuing the trial. It further
recommended changes be made to enhance the measurement of the safety and
efficacy of REOLYSIN® in the intended patient population in future studies. The
physician investigators have also made observations during the care of the six patients
that may lead to protocol changes. As is standard practice, until the clinical data and
proposed changes have been reviewed and approved by the regulatory agencies, no
new patients are being enrolled.

"We are very pleased with the interim safety data from this human study," said George
M. Gill, M.D., Oncolytics` Senior Vice President of Clinical and Regulatory Affairs. "We
have learned a great deal about the use of REOLYSIN® and, after discussing these
clinical results with the regulatory agencies, our data safety monitoring board and our
advisors, we plan to incorporate this experience into our current study and in the
design of future trials during the continued clinical development of REOLYSIN®."

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of
the human reovirus (REOLYSIN®) as a potential cancer therapeutic. Oncolytics`
researchers have demonstrated that the reovirus is able to selectively kill cancer cells
and, in vitro, kill human cancer cells derived from many types of cancer including
breast, prostate, pancreatic and brain tumours. Research has also yielded successful
cancer treatment results in a number of animal models. Phase I clinical trial results
have indicated that there were no toxicology-related issues with the administration of
the reovirus, and that the reovirus demonstrated activity in injected tumours.

This news release contains forward looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward looking statements,
including the Company`s belief as to the potential of REOLYSIN® as a component of
the treatment for recurrent malignant glioma and other cancers, and the Company`s
expectations as to the design, timing and success of its planned clinical trial programs,
involve known and unknown risks and uncertainties, which could cause the Company`s
actual results to differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to
pursue research and development projects, the efficacy of REOLYSIN® as a cancer
treatment, the success and timely completion of clinical studies and trials, the
Company`s ability to successfully commercialize REOLYSIN®, uncertainties related to
the research and development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment. Investors
should consult the Company`s quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and uncertainties relating to
the forward looking statements. Investors are cautioned against placing undue reliance
on forward looking statements. The Company does not undertake to update these
forward looking statements.



Source: Oncolytics Biotech Inc.

[Bombenleger]

Oncolytics stock up on positive brain cancer data
Monday January 6, 11:33 am ET

TORONTO, Jan 6 (Reuters) - Shares of Oncolytics Biotech (Toronto:ONC.TO - News;
NasdaqSC:ONCY - News) jumped by more than a third on Monday, on what company officials
and analysts speculated was a delayed reaction to a December announcement that its
treatment for brain cancer was well tolerated in five out of six patients.

Shares of Oncolytics were up nearly 40
percent in Toronto and 42 percent in the
Unites States in the morning. They were
up 74 Canadian cents at C$2.63 on the
Toronto Stock Exchange and rose 50
cents to $1.69 on Nasdaq.

Oncolytics said on Dec 23 that results
from its Phase I trial showed its
Reolysin treatment for brain cancer kept
five out of six patients alive. The patients
had been treated between 10 weeks and
25 weeks.

The Calgary-based company said an
independent data safety monitoring
board recommended continuing the trial
as well as changes to enhance the
measurement and efficacy of Reolysin in patients in future studies.

"Nothing really happened to the stock that day. I did not expect anything to happen," said
Shameze Rampertab, an analyst with Canaccord Capital, which helped Oncolytics raise C$2
million ($1.3 million) through a share offering in December.

"While (five out of six) is a good number, it is not statistically significant," he added. "This trial
needs to come to come to its full conclusion before we can make any kind of speculation on its
statistical significance."

Brad Thompson, chief executive of Oncolytics, said: "Some (institutional investors) out of the
United States decided to buy the stock on the open market. There is nothing material going on
in the company."

[Bombenleger]

Oncolytics Biotech Inc. Announces Completion of
Manufacturing Process Development for REOLYSIN(R)
Thursday February 6, 8:32 am ET

CALGARY, Feb. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:
ONCY) (`Oncolytics`) today announced the successful completion of its program for the
development of a commercial process for the manufacturing of REOLYSIN®.

"The ability to manufacture a drug
easily and inexpensively is a key
component of the profile of a successful
drug. When this process is run at a
commercial scale, it should meet two
key objectives, the ability to comply
with regulatory guidelines for GMP
manufacturing and the desire to be
competitive with production costs of
non-biological anti-cancer drugs," said
Dr. Brad Thompson, Oncolytics`
President and CEO. "At the current
scale of operations, one manufacturing
run should supply sufficient material for
all of our anticipated clinical studies for
the next two years."

The process development program was
conducted at BioReliance Corporation (Rockville, Maryland), a leading contract service
organization. As an example of the productivity of the manufacturing process, with a single
dose of REOLYSIN® presently expected to be from 10(9) to a maximum of 10(10) PFUs
(plaque forming units - a measure of live virus particles), each litre of primary cell culture could
produce 100 to 1,000 doses of this purified final product. Oncolytics has filed selective patent
applications with respect to the new manufacturing process.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company focused on the development of the human reovirus
(REOLYSIN®) as a potential cancer therapeutic. Oncolytics` researchers have demonstrated
that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells
derived from many types of cancer including breast, prostate, pancreatic and brain tumours.
Research has also yielded successful cancer treatment results in a number of animal models.
Phase I clinical trial results have indicated that there were no toxicology- related issues with
the administration of the reovirus, and that the reovirus demonstrated activity in injected
tumours.

This news release contains forward looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward looking statements, including the
Company`s belief as to: the ability of its manufacturing process to comply with applicable
regulatory requirements and to produce REOLYSIN® at anticipated scales and on a
cost-effective basis; the ability of the Company to produce sufficient material for the Company`s
anticipated clinical studies for the next two years; the timely receipt of necessary regulatory
approvals for the Company`s manufacturing process; the Company`s expectations that patents
will issue with claims having substantially the same scope as filed and its belief as to the
potential of REOLYSIN® as a component of the treatment for various types of cancers, and the
Company`s expectations as to the design, timing and success of its planned clinical trial
programs, involve known and unknown risks and uncertainties, which could cause the
Company`s actual results to differ materially from those in the forward looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to pursue
product manufacturing as well as research and development projects, the efficacy of
REOLYSIN® as a cancer treatment, the success and timely completion of clinical studies and
trials, the failure of the Company to receive regulatory approval of its manufacturing process in a
timely manner; the Company`s failure to successfully commercialize REOLYSIN® or to
manufacture REOLYSIN® on a commercial basis, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the regulatory process and general
changes to the economic environment. Investors should consult the Company`s quarterly and
annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward looking statements. Investors are cautioned
against placing undue reliance on forward looking statements. The Company does not
undertake to update these forward looking statements.



Source: Oncolytics Biotech Inc.

[Bombenleger]

Oncolytics Biotech Inc. Announces Completion of
Animal Toxicology Program Examining Systemic
Delivery of REOLYSIN(R)
Friday February 14, 8:30 am ET

CALGARY, Feb. 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:
ONCY) (`Oncolytics`) today announced the successful completion of its animal toxicology
program examining the systemic delivery of REOLYSIN®.

"Each route of administration of a drug must be examined for toxicology in animals before filing
applications with regulatory agencies to start human clinical trials," said Dr. Brad Thompson,
Oncolytics` President and CEO. "Oncolytics has now successfully completed nine toxicology
studies examining three different routes of administration of REOLYSIN® and the product
appears to be well tolerated in all three animal species to which it has been systemically
administered."

In the most recently completed study, small primates received REOLYSIN® daily via
intravenous infusion for a period of 28 days. At the maximum daily dose used in the study,
each primate received daily from 10 to 100 times the expected maximum single human dose
per unit of body weight. The product was well tolerated and no product-related serious adverse
events were observed.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company focused on the development of the human reovirus
(REOLYSIN®) as a potential cancer therapeutic. Oncolytics` researchers have demonstrated
that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells
derived from many types of cancer including breast, prostate, pancreatic and brain tumours.
Research has also yielded successful cancer treatment results in a number of animal models.
Phase I clinical trial results have indicated that there were no toxicology- related issues with
the administration of the reovirus, and that the reovirus demonstrated activity in injected
tumours.

This news release contains forward looking statements, within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward looking statements, including the Company`s belief as to: the
Company`s expectations as to the safety and efficacy of REOLYSIN®
including application by systemic delivery; the correlation of the animal
data to potential results in humans and the Company`s expectations as to
the design, timing and success of its planned clinical trial programs,
involve known and unknown risks and uncertainties, which could cause the
Company`s actual results to differ materially from those in the forward
looking statements. Such risks and uncertainties include, among others,
the efficacy of REOLYSIN® as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the
research and development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment.
Investors should consult the Company`s quarterly and annual filings with
the Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward looking statements.
Investors are cautioned against placing undue reliance on forward looking
statements. The Company does not undertake to update these forward
looking statements.



Source: Oncolytics Biotech Inc.

[Bombenleger]

Oncolytics Biotech Inc. Announces Issuance of
Sixth U.S. Patent
Wednesday March 5, 8:31 am ET

CALGARY, March 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC,
NASDAQ: ONCY) (`Oncolytics`) has been granted U.S. Patent 6,528,305 entitled
"Method of Producing Infectious Reovirus". This patent covers a method of producing
infectious mammalian reovirus, which is developed to be suitable for clinical
administration to mammals, including humans, on a cost effective basis.

"With the issuance of this U.S.
patent, we continue to strengthen
the Company`s intellectual property
position. The Company is
continuing to broaden its position in
this novel therapeutic area. We
currently have over 100 additional
patent applications pending
worldwide and we expect to
continue to expand our patent
portfolio for REOLYSIN®," said Dr.
Matt Coffey, Vice President of
Product Development.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based
biotechnology company focused on
the development of REOLYSIN®, its proprietary formulation of the human reovirus, as a
potential cancer therapeutic. Oncolytics` researchers have demonstrated that the
reovirus is able to selectively kill human cancer cells in vitro that are derived from many
types of cancer, including breast, prostate, pancreatic and brain tumours, and have
also demonstrated successful cancer treatment results in a number of animal models.
Phase I clinical trial results have indicated that there were no toxicology-related issues
with the administration of the reovirus, and that the reovirus demonstrated activity in
tumours injected with REOLYSIN®.

This press release contains forward looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward looking statements,
including the Company`s belief as to the potential and suitability of REOLYSIN® as a
cancer therapeutic, the Company`s expectations regarding the issuance of additional
patents and the benefits provided by current and prospective patents, and the
Company`s ability to protect its intellectual property, involve known and unknown risks
and uncertainties, which could cause the Company`s actual results to differ materially
from those in the forward looking statements. Such risks and uncertainties include,
among others, the availability of funds and resources to pursue research and
development projects, the efficacy of REOLYSIN® as a cancer treatment, the success
and timely completion of clinical studies and trials, the Company`s ability to successfully
commercialize REOLYSIN®, including the ability to commercialize REOLYSIN® in a cost
effective manner, the development of alternative products or treatments by the
Company`s competitors, the inability of the Company to defend its patents from
infringement by third parties, the risk that the Company`s patents may be subsequently
shown to be invalid, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and general changes
to the economic environment. Investors should consult the Company`s quarterly and
annual filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward looking statements.
Investors are cautioned against placing undue reliance on forward looking statements.
The Company does not undertake to update these forward looking statements.



Source: Oncolytics Biotech Inc.

[Bombenleger]

Oncolytics Biotech Inc. Reports Highlights and Financial
Results for 2002
Friday March 14, 7:00 am ET

CALGARY, March 14 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
("Oncolytics") today reported its financial results for the year ended December 31, 2002.

Highlights of 2002:
-------------------

- Positive final results from a Phase I human clinical trial for
REOLYSIN(R)
- Commencement of human clinical trials for T2 prostate cancer and
brain cancer (malignant gliomas) for REOLYSIN(R)
- Development of a commercial manufacturing process for REOLYSIN(R)
- Two additional U.S. patents and the first European patent covering
the reovirus technology were issued
- Strengthening of management and the board with the addition of George
Gill, M.D., George Masters and William Cochrane, O.C., M.D.


"During 2002, we made significant progress in advancing the development of REOLYSIN®," said Dr. Brad
Thompson, President and CEO of Oncolytics Biotech Inc. "We are steadily assembling and strengthening
the building blocks necessary to develop a novel and commercially successful cancer therapeutic."

Total loss for the year ended December 31, 2002 was $6,091,486 or $0.30 per share, compared to a loss
of $6,171,461 or $0.34 per share for the previous year, with a loss of $1,542,184 or $0.07 per share for the
three months ended December 31, 2002 as compared to a loss of $1,355,736 or $0.08 per share for the
three months ended December 31, 2001.

Total expenses for the year ended December 31, 2002 were $6,960,252 as compared to $7,137,243 for
2001. The decrease is primarily attributable to the absence of a $1.0 million milestone payment to founding
shareholders in 2002 (a $1.0 million milestone payment was paid to founding shareholders in 2001) offset
by increased product development and clinical trial activities in 2002, and increased operating activities
supporting corporate activities. In addition, increased recovery of future income taxes, further reduced the
total loss for 2002 relative to 2001.

The Company recorded reduced interest income of $208,867 in 2002 ($655,212 in 2001) resulting from
lower average cash and investment balances during the year and lower interest rates.

The Company follows the liability method of accounting for income taxes, which resulted in a future income
tax recovery of $647,618 in 2002, increased from a recovery of $340,570 recorded in 2001. The increased
recovery in 2002 reflects the effect of changes in tax rates in 2002 and recognition of loss carry forwards.

The Company had cash and cash equivalents of $8,319,244 at December 31, 2002, which compares to
cash and cash equivalents of $14,970,756 at December 31, 2001. During the year the Company raised net
proceeds of $1,769,877 from a private placement and $34,000 from the exercise of stock options. These
proceeds will be used to further the development and testing of the Company`s products as well as for
general corporate purposes.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company focused on the development of REOLYSIN®, its proprietary
formulation of the human reovirus, as a potential cancer therapeutic. Oncolytics` researchers have
demonstrated that the reovirus is able to selectively kill cancer cells and, in vitro, kill human cancer cells
derived from many types of cancer including breast, prostate, pancreatic and brain tumours. Research has
also yielded successful cancer treatment results in a number of animal models. Phase I clinical trial
results have indicated that there were no toxicology-related issues with the administration of the reovirus,
and that the reovirus demonstrated activity in injected tumours.

This press release contains forward looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward looking statements, including the Company`s belief as to
the potential of REOLYSIN® as a cancer therapeutic and the Company`s
expectations as to the success of its research and development programs
in 2003 and beyond, involve known and unknown risks and uncertainties,
which could cause the Company`s actual results to differ materially from
those in the forward looking statements. Such risks and uncertainties
include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN® as a
cancer treatment, the success and timely completion of clinical studies
and trials, the Company`s ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of
pharmaceuticals, uncertainties related to the regulatory process and
general changes to the economic environment. Investors should consult the
Company`s quarterly and annual filings with the Canadian and U.S.
securities commissions for additional information on risks and
uncertainties relating to the forward looking statements. Investors are
cautioned against placing undue reliance on forward looking statements.
The Company does not undertake to update these forward looking
statements.

Oncolytics Biotech Inc.

BALANCE SHEETS

As at December 31


2002 2001
$ $
---------------------------
ASSETS
Current
Cash and cash equivalents 8,319,244 14,970,756
Accounts receivable 48,536 95,321
Prepaid expenses 77,158 24,189
---------------------------
8,444,938 15,090,266

Capital assets 4,516,813 3,982,293

Investments 5,006,503 -
---------------------------

17,968,254 19,072,559
---------------------------
---------------------------

LIABILITIES AND SHAREHOLDERS` EQUITY
Current
Accounts payable and accrued liabilities 1,260,239 2,321,063
---------------------------
Alberta Heritage Foundation loan 150,000 150,000
---------------------------
Future income tax liability - 647,618
---------------------------
Commitments and contingency

Shareholders` equity
Share capital
Authorized: unlimited
Issued: 22,145,284 (2001 - 19,191,395) 30,305,858 23,812,953
Contributed surplus 2,702,718 2,500,000
Deficit (16,450,561) (10,359,075)
---------------------------
16,558,015 15,953,878
---------------------------

17,968,254 19,072,559
---------------------------
---------------------------



Oncolytics Biotech Inc.

STATEMENTS OF LOSS AND DEFICIT


For the years ended December 31

Cumulative
from
inception on
April 2,
2002 2001 2000 1998
$ $ $ $
------------------------------------------------------

Revenue
Rights revenue - - 310,000 310,000
Interest income 208,867 655,212 905,690 1,772,678
------------------------------------------------------
208,867 655,212 1,215,690 2,082,678
------------------------------------------------------

Expenses
Research and
development 4,283,743 5,116,661 3,689,815 13,576,881
Operating 2,102,272 1,555,128 1,060,643 4,807,073
Amortization 574,237 465,454 205,196 1,246,566
------------------------------------------------------
6,960,252 7,137,243 4,955,654 19,630,520
------------------------------------------------------

Loss before
income tax 6,751,385 6,482,031 3,739,964 17,547,842

Income tax recovery (659,899) (310,570) (126,812) (1,097,281)
------------------------------------------------------

Net loss for
the year 6,091,486 6,171,461 3,613,152 16,450,561

Deficit, beginning
of year 10,359,075 4,187,614 574,462 -
------------------------------------------------------
Deficit, end of
year 16,450,561 10,359,075 4,187,614 16,450,561
------------------------------------------------------
------------------------------------------------------

Basic and diluted
loss per share (0.30) (0.34) (0.22)
-----------------------------------------
-----------------------------------------



Oncolytics Biotech Inc.

STATEMENTS OF CASH FLOWS


For the years ended December 31

Cumulative
from
inception on
April 2,
2002 2001 2000 1998
$ $ $ $
------------------------------------------------------

OPERATING ACTIVITIES
Net loss for
the year (6,091,486) (6,171,461) (3,613,152) (16,450,561)
Deduct non-cash
items
Amortization 574,237 465,454 205,196 1,246,566
Income tax
recovery (647,618) (340,570) (126,812) (1,115,000)
Non-cash
compensation 32,718 - - 32,718
Net changes in
non-cash working
capital (1,123,551) 1,773,720 376,769 1,065,370
------------------------------------------------------
(7,255,700) (4,272,857) (3,157,999) (15,220,907)
------------------------------------------------------

INVESTING ACTIVITIES
Capital asset
expenditures (1,052,214) (585,513) (372,823) (2,079,200)
Investment in
Transition
Therapeutics Inc. (20,352) - - (20,352)
Investment in
BCY LifeSciences
Inc. (127,123) - - (127,123)
------------------------------------------------------
(1,199,689) (585,513) (372,823) (2,226,675)
------------------------------------------------------

FINANCING ACTIVITIES
Alberta Heritage
Foundation loan - - - 150,000
Proceeds from
exercise of stock
options and
warrants 34,000 2,210,016 501,010 2,760,103
Proceeds from
private placement 1,769,877 - 2,998,645 6,673,520
Proceeds from
issue of
common shares - - 13,101,100 16,183,203
------------------------------------------------------
1,803,877 2,210,016 16,600,755 25,766,826
------------------------------------------------------

Increase (decrease)
in cash and cash
equivalents
during the year (6,651,512) (2,648,354) 13,069,933 8,319,244

Cash and cash
equivalents,
beginning of
the year 14,970,756 17,619,110 4,549,177 -
------------------------------------------------------

Cash and cash
equivalents,
end of the year 8,319,244 14,970,756 17,619,110 8,319,244
------------------------------------------------------
------------------------------------------------------

Cash interest
received 218,129 655,212 905,690
----------------------------------------
----------------------------------------

Cash taxes paid 18,114 39,870 -
----------------------------------------
----------------------------------------



Source: Oncolytics Biotech Inc.

[Bombenleger]

Oncolytics Biotech Inc. Announces Results of
Reovirus Treatment to Purge Stem Cell Preparations
of Contaminating Cancers
Wednesday March 19, 8:30 am ET

CALGARY, March 19 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:
ONCY) (`Oncolytics`) reported today that Dr. Don Morris and his research group with the Alberta
Cancer Board and the University of Calgary published the results of their work with the human
reovirus for the removal of contaminating cancer cells from autologous (harvested from the
patient themselves) blood stem cells in model systems. The results were prepublished online in
the March 13th, 2003 issue of Blood.

"This is an important extension of the
potential therapeutic use of the reovirus
beyond what has recently been
explored," said Dr. Matt Coffey, Vice
President Product Development. "We
are excited by the potential
opportunities to use this agent clinically
in diverse and evolving capacities."

Hematological (derived from blood) stem
cell rescue following high-dose
chemotherapy is extensively used
clinically for both solid tumors and
tumors of the blood. Globally, the
number of autologous blood and bone
marrow transplants surpasses the
number of donor-derived transplants. It
has been estimated that as many as
30% of these autologous stem cell transplants are contaminated by cancer cells. Dr. Morris
and his colleagues demonstrated that reovirus purged contaminating cancer cells present in
these stem cells derived from bone marrow.

In addition, two recent publications addressed different elements of research into the use of the
human reovirus as a potential cancer therapeutic. Hirasawa et al. in the January 15th edition of
Cancer Research demonstrated the use of the reovirus in treating metastatic disease in animal
models using the reovirus delivered systemically. This is the first published examination of the
systemic use of the reovirus in immune competent animals. Etoh et al in the March 9th edition
of Clinical Cancer Research examined the use of the reovirus to kill pancreatic cancers both in
vitro and in animal models.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of
REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer
therapeutic. Oncolytics` researchers have demonstrated that the reovirus is able to selectively
kill human cancer cells in vitro that are derived from many types of cancer, including breast,
prostate, pancreatic and brain tumours, and have also demonstrated successful cancer
treatment results in a number of animal models. Phase I clinical trial results have indicated that
there were no toxicology-related issues with the administration of the reovirus, and that the
reovirus demonstrated activity in tumours injected with REOLYSIN®.

This news release contains forward looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward looking statements, including the
Company`s belief as to the use of the human reovirus as a potential cancer therapeutic, involve
known and unknown risks and uncertainties, which could cause the Company`s actual results
to differ materially from those in the forward looking statements. Such risks and uncertainties
include, among others, the efficacy of REOLYSIN® as a cancer treatment, the success and
timely completion of clinical studies and trials, uncertainties related to the research and
development of pharmaceuticals, uncertainties related to the regulatory process and general
changes to the economic environment. Investors should consult the Company`s quarterly and
annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward looking statements. Investors are cautioned
against placing undue reliance on forward looking statements. The Company does not
undertake to update these forward looking statements.



Source: Oncolytics Biotech Inc.

[Bombenleger]

Oncolytics Biotech Inc. Reports Presentation of
Results From Interim Assessment of T2 Prostate
Cancer Trial
Monday March 31, 8:31 am ET

CALGARY, March 31 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ:
ONCY) (`Oncolytics`) reports that Dr. Don Morris of the Alberta Cancer Board and the University
of Calgary presented results from an interim assessment of the first six completed patients of a
clinical study to evaluate the efficacy and safety of REOLYSIN® for the treatment of T2
prostate cancer. There was evidence of viral activity in five of six patients and there were no
safety concerns, from either a clinical or histopathological perspective, in all six patients. The
results were presented March 28th, 2003 at a conference on "Oncolytic Viruses As Cancer
Therapeutics" held in Banff, Alberta.

The preliminary data showed clear
histopathological evidence of apoptotic
tumour cell death, one measure of viral
activity, in four of the six patients. In a
fifth patient, the PSA level dropped by
53% and the prostate gland shrank by
67% from just prior to treatment to the
time of surgical removal. There was no
evidence of viral activity in the sixth
patient. In all six patients, there was no
histopathological evidence of any viral
effect on healthy prostatic tissue.

"We are pleased with the preliminary
results from this trial," said Dr. Brad
Thompson, Oncolytics` President and
CEO. "This preliminary data shows
histopathological evidence that
REOLYSIN® selectively infects and kills tumour cells in humans. Our future clinical trials will
examine systemic administration of REOLYSIN® that will target metastatic disease. Advanced
prostate cancer will be considered for one of these trials."

The T2 prostate cancer trial is intended to evaluate the histopathological efficacy of
intra-tumoural administration of REOLYSIN® for the treatment of cancer that is restricted to the
prostate gland. Patients will receive a single injection of REOLYSIN® and will be monitored for
approximately three weeks, at which time the prostate will be surgically removed. The primary
efficacy endpoint will be the response rate as measured by pathological examination of the
tumour.

Cancer of the prostate is one of the most common cancers in men, representing approximately
one-third of all male cancers in western society. It is second only to lung cancer as the leading
cause of cancer deaths in men. There were an estimated 18,200 new cases of prostate cancer
in Canada in 2002 and the American Cancer Society estimates that there will be 220,900 new
cases in the US in 2003.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of
REOLYSIN®, its proprietary formulation of the human reovirus, as a potential cancer
therapeutic. Oncolytics` researchers have demonstrated that the reovirus is able to selectively
kill human cancer cells in vitro that are derived from many types of cancer, including breast,
prostate, pancreatic and brain tumours, and have also demonstrated successful cancer
treatment results in a number of animal models. Phase I clinical trial results have indicated that
REOLYSIN® was well tolerated and that the reovirus demonstrated activity in tumours injected
with REOLYSIN®.

This news release contains forward looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward looking statements, including the
Company`s belief as to: the Company`s expectations as to the safety and efficacy of
REOLYSIN® including application by systemic delivery; and the Company`s expectations as to
the design, timing and success of its planned clinical trial programs, involve known and
unknown risks and uncertainties, which could cause the Company`s actual results to differ
materially from those in the forward looking statements. Such risks and uncertainties include,
among others, the efficacy of REOLYSIN® as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the research and development
of pharmaceuticals, uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company`s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional information on risks and
uncertainties relating to the forward looking statements. Investors are cautioned against placing
undue reliance on forward looking statements. The Company does not undertake to update
these forward looking statements.



Source: Oncolytics Biotech Inc.

[daskommtso]

Gibt es da auch mal einen Text in Deutsch ??